Healthcare
Hikal Limited Earns Ecovadis Gold Medal, Ranking in Top 5% Globally for Sustainability Performance
Hikal Limited (NSE: HIKAL) earns EcoVadis Gold Medal, ranking in top 5% globally for sustainability performance.
Hikal Limited, a leading partner to global pharmaceutical, crop protection, and specialty chemical companies, has been awarded the EcoVadis Gold Medal rating, placing it among the top 5% of more than 175,000 companies assessed globally by EcoVadis each year. The company achieved an overall score of 84/100 and a 97th percentile ranking in the EcoVadis assessment. This recognition reflects Hikal’s continued commitment to sustainable business practices and performance across the four key pillars of the EcoVadis assessment: Environment, Labour & Human Rights, Ethics, and Sustainable Procurement.
Commitment to Sustainability
Commenting on the development, Sameer Hiremath, Vice Chairman and Managing Director of Hikal, said: “This recognition underscores Hikal’s commitment to embedding sustainability into its business strategy and operating culture. Our EcoVadis Gold Medal reflects the progress we have made across environmental stewardship, responsible manufacturing, ethical business practices, and sustainable procurement, and it strengthens our resolve to continue delivering long-term value through responsible growth.”
Strengthening Credibility
The rating is particularly relevant for companies operating in global life sciences and specialty chemicals supply chains, where customers increasingly expect suppliers to demonstrate measurable progress on sustainability, ethics, labour practices, and responsible sourcing. The Gold Medal reinforces Hikal’s Environmental, Social, and Governance performance and demonstrates the company’s focus on responsible manufacturing, robust governance practices, and sustainable value creation for all its stakeholders. The achievement further strengthens Hikal’s credibility with global customers and investors, many of whom use EcoVadis ratings as an important criterion in supplier evaluation and partnership decisions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Hikal Limited
Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Hikal drops 29.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 3 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock sits at 5% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -1.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 29.1% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Hikal Limited.
ALIVUS
Alivus Life Sciences Limited (alivus) Q2fy27: Revenue Up 16.0% Yoy, Ebitda Margin at Record High
Alivus Life Sciences Limited (NSE: ALIVUS) announced Q2FY27 results with 16.0% YoY revenue growth, EBITDA margin at 41.8%, and strong cash flow.
Alivus Life Sciences Limited (NSE: ALIVUS) announced its financial results for the second quarter and half-year ended September 30, 2026, showcasing a robust performance. Revenue from operations for Q2FY27 came at Rs. 6,820 Mn, marking a 16.0% year-over-year growth, driven by broad-based momentum in the non-GPL business which grew at 20.8% YoY. EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%, up 520 bps QoQ & 880 bps YoY, driven by favourable product mix, new launches, and the benefits of operating leverage.
Strong Financial Performance
The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.”
Future Outlook
Tushar Mistry, CFO, Alivus Life Sciences Limited said, “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix. Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. With cash and cash equivalents of Rs. 1,012 crores as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet. Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alivus Life Sciences Limited
Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alivus gains 15.6% over three months and trades near its 52-week highs. The PEG stands at 4.11 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. The stock gives back 4.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.6% in three months on 6.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.
Drug Manufacturers - General
Sanofi India Limited Board Meeting Concludes at 4:45 P.m. on October 29, 2026
Sanofi India Limited’s board meeting concluded at 4:45 p.m. on October 29, 2026, with significant focus on strategic initiatives.
Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.
Strategic Initiatives
The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.
Operational Updates
The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.
Future Outlook
As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Sanofi India Limited
Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.
Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.
Healthcare
Strides Pharma Science Limited (star) Q2fy27: Revenue Up 17% Yoy, Ex-us Markets Growth at 31% Yoy
Strides Pharma Science Limited (STAR) reports Q2FY27 revenue at ₹14,297m, up 17% YoY; Ex-US Markets growth at 31% YoY.
Strides Pharma Science Limited (STAR) announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September 2026, showcasing a strong performance. The company reported a revenue of ₹14,297 million, marking a 17% year-on-year growth, driven by a robust 31% YoY increase in the Ex-US Markets. The US business also saw a 9% YoY growth to ₹6,855 million. EBITDA rose to ₹2,509 million, crossing the ₹2,500 million mark for the first time, despite higher input material and freight costs.
Financial Highlights
The company’s operational PAT increased by 11.5% YoY to ₹1,358 million, while the reported PAT rose 2% YoY to ₹1,341 million. The operational EPS stood at ₹14.7, up from ₹13.2. The company’s diversification strategy is evident as the Ex-US Markets surpassed the US business in quarterly revenue for the first time. The company remains focused on mitigating cost pressures through continuous optimization initiatives.
Looking Ahead
Despite the dynamic external environment, Strides Pharma Science Limited is committed to delivering sustainable and profitable growth. The company expects the Net Debt to EBITDA ratio to stabilize by the end of the year. With new board member Mr. Biren Gabhawala, the company aims to strengthen its governance and oversight mechanisms.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Strides Pharma Science Limited
Strides Pharma Science Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Strides moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.6x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises -2.8% in three months on 8.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Strides Pharma Science Limited.
-
KFINTECH3 days agoKfin Technologies Limited Q2fy27: Strong Performance Driven by Broad-based Revenue Growth and Margin Expansion
-
AWL2 days agoAwl Agri Business Limited (AWL) Delivers Strong Q2 FY27 Growth; Revenue Grows 26% to INR 22,202 Crore with Operating Ebitda Up 11% Yoy
-
Consumer Cyclical2 days agoSky GOLD and Diamonds Limited (NSE: Skygold) Q2 and H1 FY27: Revenue at Rs 4,403.45 Crore, PAT Up 111.9%
-
DYCL2 days agoDynamic Cables Limited (dycl) Scaling with Strength: Q2 FY27 Results Show Strong Growth
-
Industrials2 days agoNavkar Corporation Limited Announces Q2 FY27 Results: Revenue Up 15%, Ebitda Surges 20%
-
Auto Parts2 days agoSchaeffler India Limited (NSE: Schaeffler) Q3 FY26: Double-digit Growth Across Domestic and Export Businesses
-
ACUTAAS2 days agoAcutaas Chemicals Limited (acutaas) Q2 & H1 FY27 Results: Revenue Up 42.7% Yoy, PAT Surges 71.4%
-
Consumer Cyclical2 days agoHuhtamaki India Limited Q3 FY26: Net Sales Surge 23.7%, EBIT Up 18%